| Identification | Back Directory | [Name]
2,2-bis(4-fluorophenyl)-2-phenyl-acetamide | [CAS]
289656-45-7 | [Synonyms]
ICA 17043
Senicapoc
ICA-17043;ICA 17043;ICA17043
2,2-bis(4-fluorophenyl)-2-phenyl-acetamide
4-Fluoro-A-(4-Fluorophenyl)-A-Phenyl-BenzeneacetaMide
Benzeneacetamide, 4-fluoro-α-(4-fluorophenyl)-α-phenyl-
Benzeneacetamide, 4-fluoro-a-(4-fluorophenyl)-a-phenyl-
4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide | [Molecular Formula]
C20H15F2NO | [MDL Number]
MFCD09027349 | [MOL File]
289656-45-7.mol | [Molecular Weight]
323.34 |
| Chemical Properties | Back Directory | [Melting point ]
180-181 °C(Solv: hexane (110-54-3); dichloromethane (75-09-2)) | [Boiling point ]
460.7±45.0 °C(Predicted) | [density ]
1.250±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMSO : 50 mg/mL (154.64 mM; Need ultrasonic) | [form ]
Powder | [pka]
15.41±0.50(Predicted) |
| Hazard Information | Back Directory | [Description]
Senicapoc is an inhibitor of intermediate conductance calcium-activated potassium (IKCa1/KCa3.1) channels.1,2 It inhibits rubidium efflux from and dehydration of isolated human red blood cells (RBCs) induced by the calcium ionophore A23187 (Item No. 11016; IC50s = 11 and 30 nM, respectively).1 Senicapoc (10 mg/kg twice per day) reduces IKCa1/KCa3.1 channel activity, increases potassium levels in RBCs, and decreases erythrocyte density in the SAD transgenic mouse model of sickle cell disease. It inhibits IL-2, IFN-γ, IL-12, and IL-17A production in CD3+ T cells stimulated with phorbol 12-myristate 13-acetate (PMA; Item No. 10008014) and ionomycin (Item Nos. 10004974 | 11932) when used at a concentration of 1 μM.3 Senicapoc (100 mg/kg) increases the paw withdrawal threshold in a rat model of chronic constriction injury (CCI) of the sciatic nerve.2 | [Uses]
Treatment of disorders mediated by a calcium activated intermediate conductance potassium ion channel antagonist. | [storage]
Store at -20°C |
|
|